Effects of CreaSafe® on Kidney, Muscle, and Cardiopulmonary Function in Athletes and COPD Patients

Launched by FEDERAL UNIVERSITY OF SÃO PAULO · May 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new supplement called CreaSafe®, which is a type of creatine. The goal is to see how this supplement affects kidney function, muscle strength, and breathing in two groups of people: athletes and patients with severe Chronic Obstructive Pulmonary Disease (COPD). In the trial, 80 athletes (including both strength trainers and runners) and 60 COPD patients will take either CreaSafe® or a placebo (a harmless substance with no active ingredients) for 90 days. Researchers will measure various health indicators, including kidney function and muscle strength, before and after the study period.

To participate, athletes should be resistance-trained or middle- and long-distance runners, while COPD patients must have severe or very severe disease. Unfortunately, non-athletes and those without a COPD diagnosis cannot join. Throughout the study, participants will take the supplement in the morning and undergo several tests to monitor their health. This research could help determine if CreaSafe® is a safe and effective option for enhancing athletic performance and improving health in COPD patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • resistance-trained athletes middle- and long-distance runners severe and/or very severe COPD
• Exclusion Criteria:
• • Non-athletes and individuals without a diagnosis of COPD